ClinicalTrials.gg
CompletedNCT03318471Updated Oct 24, 2017

Magnesium Sulphate for Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application

A Phase 4 interventional study of MgSo4 and 0.9% NaCl in Supratentorial Brain Tumor, sponsored by El-Sahel Teaching Hospital. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-10-24.

Sponsored by El-Sahel Teaching Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Feb 2016, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Use of Mayfield skull clamp during craniotomies; results in a sharp and intense noxious stimulus which results in a severe hemodynamic pressor response. Many strategies have been reported to blunt this undesirable pressor effect. This prospective, double blind, and randomized study is the first to evaluate the effect of MgSo4 on attenuation of hemodynamic pressor activity after head clamp application during craniotomies.

Read the detailed description

Background: Use of Mayfield skull clamp during craniotomies; results in a sharp and intense noxious stimulus which results in a severe hemodynamic pressor response. Many strategies have been reported to blunt this undesirable pressor effect. This prospective, double blind, and randomized study is the first to evaluate the effect of MgSo4 on attenuation of hemodynamic pressor activity after head clamp application during craniotomies.

Methods: This randomized, double blind, and prospective study was done in Neurosurgical department at ElSahel Teaching Hospital in Cairo from February 2016 till august 2017. All adult patients aged from 18 to 60 years of both genders, ASA physical status I and II scheduled for craniotomies were assessed to enter this study. Seventy one patients were assessed preoperatively, sixty of them were enrolled and assigned in two groups (n=30 each). Group M received 50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes. Group S received 100ml 0.9% Sodium Chloride over the same period with the same rate.Mean HR was recorded as a primary outcome , meanwhile; MAP and the need for a bolus dose of fentanyl was considered a secondary outcome.

02

Conditions studied

  • Supratentorial Brain Tumor

Browse trials for

Keywords

  • MgSo4, Mayfield clamp, pressor effect
03

In context

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

This study's enrollment of 60 is above the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

El-Sahel Teaching Hospital is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult patients aged from 18 to 60 years
  • of both genders
  • I and II
  • scheduled for craniotomies

Exclusion criteria

Exclusion Criteria:

  • history of MgSo4 consumption or allergy
  • renal disease
  • hepatic or endocrine disorder
  • cardiovascular dysfunction
  • calcium channel blocker intake
  • drug abuse were excluded from this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Group M

    received 50 mg/kg MgSo4 in 100 ml 0.9 NaCl 15 minutes prior to anesthesia induction over 15 minutes

    Drug: MgSo4

  • Placebo comparator
    Group S

    received 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes.

    Drug: 0.9% NaCl

Interventions

  • DrugMagnesium sulfate anhydrousStudies of Magnesium sulfate anhydrousMagnesium sulfate anhydrous pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes

    Also known as: magnesium sulphate

  • Drug0.9% NaCl

    100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes

    Also known as: normal saline

06

What researchers measure

Primary outcomes

  1. Mean HR

    Mean heart rate/min.

    Time frame: From time of insertion over 30 minutes period {at the time of pins insertion (Pin 0),60 seconds ( pin 60'), 5 minutes (pin 5''), 10 minutes ( pin 10''), 20 minutes ( pin 20'') and 30 minutes (pin 30'').}

Secondary outcomes

  1. MAP

    Mean arterial Blood Pressure (mmHg)

    Time frame: From time of insertion over 30 minutes period {at the time of pins insertion (Pin 0),60 seconds ( pin 60'), 5 minutes (pin 5''), 10 minutes ( pin 10''), 20 minutes ( pin 20'') and 30 minutes (pin 30'').}

  2. Need for a bolus opioid

    Need for a bolus fentanyl after pins insertion to alleviate pressor effects

    Time frame: from time of insertion over 30 minutes .

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • 1. Gonzales RM, Masone RJ, Peterson R. Hemodynamic response to application of neurosurgical skull-pin head-holder. Anesth Rev. 1987; 14:53-4.
  • Bithal PK, Dash HH, Chauhan R, Mohanty B. Haemodynamic changes in response to skull-pins application - Comparison between normotensive and hypertensive patients. Indian J Anaesth. 2002; 46:383-5.
  • Paul A, Krishna HM. Comparison between intravenous dexmedetomidine and local lignocaine infiltration to attenuate the haemodynamic response to skull pin head holder application during craniotomy. Indian J Anaesth. 2015 Dec;59(12):785-8. doi: 10.4103/0019-5049.171558. PubMed 26903671 ↗
  • Osborn I, Sebeo J. "Scalp block" during craniotomy: a classic technique revisited. J Neurosurg Anesthesiol. 2010 Jul;22(3):187-94. doi: 10.1097/ANA.0b013e3181d48846. PubMed 20479675 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Aug 2017, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2017
First posted
Oct 24, 2017
StartActual
Feb 2016
Primary completionActual
Aug 2017
CompletionActual
Oct 1, 2017
Last update
Oct 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03318471
Lead sponsor
El-Sahel Teaching Hospital
Responsible party
Samir Ahmed Ahmed ElKafrawy (Fellow of Anesthesia & Pain Relief, El-Sahel Teaching Hospital) — Principal investigator
First posted
Oct 24, 2017
Start date
Feb 2016
Primary completion
Aug 2017
Completion
Oct 1, 2017
Last update
Oct 24, 2017

Study contacts

Samir A ElKafrawy, MD
principal investigator · ElSahel Teaching hospital,Cairo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Magnesium sulfate anhydrous

Start the discussion